Profile data is unavailable for this security.
About the company
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
- Revenue in USD (TTM)0.00
- Net income in USD-104.97m
- Incorporated2017
- Employees72.00
- LocationLexeo Therapeutics Inc345 Park Avenue South, Floor 6NEW YORK 10010United StatesUSA
- Phone+1 (212) 547-9879
- Fax+1 (302) 636-5454
- Websitehttps://www.lexeotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 417.00m | 51.00 | -- | 1.56 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 421.68m | 73.00 | -- | 2.31 | -- | 11.34 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| PepGen Inc | 0.00 | -93.56m | 442.74m | 81.00 | -- | 2.71 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 444.22m | 27.00 | -- | 8.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 447.98m | 30.00 | -- | 3.65 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Verastem Inc | 13.38m | -241.11m | 449.04m | 78.00 | -- | -- | -- | 33.56 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 460.55m | 72.00 | -- | 2.87 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Ocugen Inc | 5.37m | -64.02m | 462.32m | 95.00 | -- | 124.65 | -- | 86.09 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 472.84m | 52.00 | -- | 1.25 | -- | 168.93 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 473.38m | 869.00 | -- | 1.86 | 98.87 | 1.02 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 476.92m | 227.00 | -- | 1.19 | -- | 3,974.36 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 482.26m | 100.00 | -- | 2.21 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 482.32m | 163.00 | -- | 1.64 | -- | 40.92 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 494.27m | 263.00 | -- | -- | -- | 6.57 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
Data as of Feb 17 2026. Currency figures normalised to Lexeo Therapeutics Inc's reporting currency: US Dollar USD
78.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 7.29m | 13.50% |
| RA Capital Management LPas of 20 Oct 2025 | 5.00m | 9.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.49m | 8.32% |
| Affinity Asset Advisors LLCas of 22 Jan 2026 | 4.35m | 8.06% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 3.91m | 7.25% |
| Paradigm BioCapital Advisors LPas of 13 Nov 2025 | 3.67m | 6.80% |
| Citadel Advisors LLCas of 30 Sep 2025 | 3.61m | 6.68% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.47m | 6.43% |
| Vestal Point Capital LPas of 30 Sep 2025 | 3.25m | 6.02% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.19m | 5.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
